Business Context and Reporting Period
Company: Bone Biologics Corp (BBLG)
Filing Type: Form 8-K (Current Report)
Date of Report: March 4, 2024 (Event Date)
Closing Date: March 6, 2024
Context: The Company announced and subsequently closed a public offering of common stock, warrants, and pre-funded warrants to raise capital for clinical trials, patent maintenance, and working capital.
Key Financial Metrics and Transaction Details
- Net Proceeds: Approximately $1.5 million (after deducting placement agent fees and offering expenses).
- Securities Issued:
- 119,000 shares of Common Stock + Warrants at $2.56 per unit.
- 662,251 Pre-Funded Warrants + Warrants at $2.559 per unit.
- Warrant Terms:
- Exercise Price: $2.43 per share (immediately exercisable, 5-year term).
- Pre-Funded Warrant Exercise Price: $0.001 per share.
- Placement Agent Warrants: 46,875 shares at $3.20 exercise price.
- Post-Offering Capitalization: 879,176 shares of Common Stock outstanding.
- Transaction Costs: 7.0% cash fee + 1.0% management fee to Placement Agent (H.C. Wainwright & Co., LLC), plus reimbursement of expenses up to $110,000 and clearing fees of $15,950.
Material Changes Versus Prior Period
This filing represents a discrete capital event rather than a periodic financial report. Consequently, there are no comparative revenue, profit, or cash flow metrics provided in this document. The primary material change is the increase in outstanding share count to 879,176 shares and the dilution associated with the issuance of warrants and pre-funded warrants.
Guidance, Outlook, and Covenants
- Use of Proceeds: Funding clinical trials, maintaining/extending patent portfolio, and general working capital.
- Lock-Up Covenants:
- 60-day prohibition on issuing Common Stock or convertible securities post-closing.
- 1-year prohibition on entering into variable rate transactions post-closing.
- Ownership Limitations: Warrant holders cannot exercise if it would result in beneficial ownership exceeding 4.99% (or 9.99% at election) of outstanding shares.
- Risks/Contingencies: The filing notes that the Placement Agent was not required to arrange a minimum purchase amount, indicating the offering was best-efforts based.
Investor Verification Checklist
- Verify the exact number of shares outstanding (879,176) and the dilution impact of the 781,251 total warrants issued (including pre-funded and placement agent warrants).
- Confirm the cash burn rate relative to the $1.5 million net proceeds to assess runway for clinical trials.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific termination rights and indemnification obligations.
- Monitor compliance with the 60-day issuance lock-up and 1-year variable rate transaction prohibition.
- Check subsequent filings for the actual exercise of pre-funded warrants, which will convert to common stock at a nominal price.